Our Promise: One pill, one bottle, one prescription, one refill, one dispensing fee, one co-pay, once-a-day.

Product Overview

CardioPharma, Inc. is focused on the global development of combinatorial cardiovascular products.

The company’s pipeline is cardiovascular disease – pharmaco-economic-centric – designing products to be highly cost-effective, targeting reduced expenditures at all levels, with proven efficacy, and providing both patient and provider convenience in order to minimize what has become an epic problem throughout healthcare: compliance. At CardioPharma, we believe our products are in the right place at the right time!

While CardiaPill®, the lead product of CardioPharma, broadly targets cardiovascular disease, pipeline products focus on specific cardiovascular disease patient populations, such as metabolic syndrome and diabetes, as well as different components to better meet the needs of these populations.

The company’s pipeline is backed by intellectual property that has issued in the US, EU and other international markets. CardioPharma believes that additional anticipated patents will further strengthen our company’s future.

The principal elements of our strategy comprise:

  • Aggressively advancing our cardiovascular product candidates
  • Successfully commercializing our products throughout the world
  • Establishing cost-effective compliance-based global cardiovascular disease treatment protocols
  • Continuing to build our strong management and scientific expertise
  • Building strategic relationships that enhance and complement our own product development and commercial organization
  • Protecting and enhancing the intellectual property surrounding our products
  • Putting all patients first with cost-effective products created to help mitigate the devastating effects of the world’s number one killer, cardiovascular disease